Biotech Startups

GEXVal is a pharmaceutical company focused on researching and developing medicines for difficult-to-treat and rare diseases. The company is based in Japan with operations including a subsidiary in Australia.

1 investor

GFBiochemicals develops plant-based chemical ingredients derived from levulinate technology to replace harmful petrochemical components in consumer products such as shampoos, detergents, and cosmetics. The company operates manufacturing and research facilities across Europe and Asia, targeting reduction of carbon emissions and chemical pollution in everyday household and personal care products.

1 investor

GFC Life Science (지에프씨생명과학) develops cosmetic ingredients based on skin microbiome research and plant cell cultivation, including exosome and miRNA-based materials from its proprietary strain library. Its clinical division conducts dermatologist-led safety and efficacy testing for cosmetics, including regulatory evaluations for wrinkles, whitening, and hair loss.

1 investor

Ghiaroni selects and distributes laboratory products, including consumables and instrumentation, and provides design, setup, and after-sales maintenance services to scientific laboratories. It operates in Italy as a member of the CDL consortium for the distribution of scientific laboratory articles.

1 investor

GHO Capital is a venture capital firm focused on healthcare innovation, specifically supporting pharmaceutical and biotechnology companies with product development and manufacturing solutions.

1 investor

GI Cell is a South Korean biotech company developing allogeneic NK (natural killer) cell therapies and CAR-NK cancer treatments. It works on high-purity, high-efficiency NK cell culture technology and partners with other firms to develop immunotherapies.

1 investor

GIE Medical is a clinical-stage medical device company developing the ProTractX3, a drug-coated balloon for treating benign strictures of the esophagus and bowel. It is conducting clinical trials in the United States aimed at offering gastroenterology patients sustained patency and fewer repeat treatments.

1 investor

Gilly makes a prebiotic feed additive derived from an anaerobic gut fungus that helps cattle digest more fiber, letting producers turn ordinary forage and low-cost byproducts into more milk and meat while improving feed efficiency and lowering cost. It serves dairy and beef cattle producers in the animal agriculture industry.

1 investor

Girihlet develops a diagnostic tool to monitor autoimmune treatments, helping patients and the doctors treating them select the most effective therapies. The company has established a collaboration with the Mayo Clinic to study the use of its ImmuneScanner tool in evaluating treatment effects on Ankylosing Spondylitis.

1 investor

GIVAX is a biotechnology company focused on vaccine development. The company's board includes scientific expertise in virology and venture capital backing from leading biotech investors.

1 investor

Glacies offers a clinic CRM delivered as software-as-a-service, combining a staff web application for appointments, patient records, treatment plans, and reporting with a client-facing mobile journey for care planning and follow-up. It targets aesthetic and skin clinics and includes an optional layer of skin microbiome sequencing insights.

1 investor

Glenclova Scientific develops a virus-like particle (VLP) platform that displays therapeutic proteins and peptides to enhance the efficacy and reduce the dosage requirements of biologic drugs. The platform targets chronic disease treatments, particularly for inflammatory, respiratory, dermatological, and oncological indications, with a focus on improved accessibility and affordability for resource-limited healthcare settings.

1 investor

GLIA Diagnostics is an Australian medtech company developing a point-of-care platform that uses a multiplex circulating microRNA biomarker panel to provide objective biological information following traumatic brain injury, including mild TBI and concussion. The system, still investigational, combines a blood sample, cartridge and handheld reader targeting an approximately 20-minute result for use in clinical, sport and defence settings.

1 investor

GlioCART develops a dual-action CAR-T cell therapy for glioblastoma that targets tumor cells while reprogramming tumor-supporting myeloid cells into active immune effectors. The company aims to extend CAR-T therapy to solid tumors and other myeloid-driven cancers.

1 investor

1 investor

Global Cord Blood Corporation is China's leading provider of umbilical cord blood collection, laboratory testing, and hematopoietic stem cell processing and storage services. The company operates as a specialized biobank serving patients and families seeking cord blood banking and stem cell therapies.

1 investor

GlucoSentient develops diagnostic assays based on functional DNA (DNAzymes and aptamers) and nanomaterials for sensing applications. The company applies this biosensing technology to the diagnostics and medical testing field.

1 investor

Glycologix is a clinical-stage biotechnology company developing locally delivered biopolymers that mimic natural proteoglycans for the protection and repair of soft tissues. Its lead program, GLX-100, targets interstitial cystitis/bladder pain syndrome (IC/BPS), with the technology intended for additional soft tissue indications.

1 investor

GlycoSpot develops enzyme testing technology that enables rapid quality control of enzyme activity for industrial bioprocess applications. The platform helps industries transition to bio-based production processes by providing quick, cost-effective measurement solutions without requiring specialized expertise.

1 investor

Glycotest develops diagnostic tests for the early detection of liver disease and liver cancer. The company operates in the biomedical diagnostics field within the healthcare industry.

1 investor

Glyscend Therapeutics is a clinical-stage biopharmaceutical company developing oral, first-in-class therapies for type 2 diabetes and obesity. Its approach originated from research on how certain bariatric surgeries improve glucose and metabolic regulation and produce sustained weight loss.

1 investor

Gnomica develops small-molecule drug inhibitors that target bacterial pathways as a treatment for cancer.

1 investor

Aitia builds the Gemini Digital Twin platform, which combines causal AI and a reverse-engineering/forward-simulation (REFS) engine with supercomputing and patient multiomic and clinical data to create in silico models of human disease biology. The models identify novel causal drug targets and biomarkers that biopharma partners use to develop precision drugs for oncological, neurodegenerative, immunological, and cardiometabolic diseases.

1 investor

GOA Therapeutics is a biotech company developing GOA26, a drug candidate aimed at addressing the health harms of excessive alcohol drinking, advanced through protein engineering, formulation, and IND-enabling testing in porcine models. The candidate is progressing toward IND filing and clinical studies for emergency and trauma care settings.

1 investor